Search results for "Tumor Response"
showing 10 items of 10 documents
Effect of Kernels Used for the Reconstruction of MDCT Datasets on the Semi-Automated Segmentation and Volumetry of Liver Lesions
2014
Purpose: To evaluate the effect of different reconstruction kernels on the semi-automated segmentation of liver lesions in MDCT. Materials and Methods: A total 62 liver lesions were measured by three independent radiologists with the semi-automated segmentation software Oncology-Prototype (Fraunhofer MEVIS, Siemens Healthcare, Germany) using MDCT datasets (3-mm slice thickness, 2-mm increment) reconstructed with standard, soft and detailed kernels (Philips B, A and D). To ensure objective measurements, only lesions with satisfactory initial segmentation were included, and manual correction was not used. The effective diameter and volume were recorded for each lesion. Segmentation in the sof…
Tumor response assessment by Choi criteria in localized high-risk soft tissue sarcoma (STS) treated with chemotherapy (CT): Update at 10-year follow-…
2016
11044Background: We already reported (Cancer 2012;118:5857) on better correlation of Choi criteria (Choi) than RECIST with the outcome of pts affected by high-risk STS entering a multicentric Itali...
Pathophysiology of Solid Tumors
2009
It is generally accepted that tumor blood flow, microcirculation, oxygen and nutrient supply, tissue pH distribution, lactate levels, and the bioenergetic status— factors that are usually closely linked and that define the so-called pathophysiological microenvironment (“tumor pathophysiome”)—can markedly influence the therapeutic response of malignant tumors to conventional irradiation, chemotherapy, other non-surgical treatment modalities, malignant progression, and the cell proliferation activity within tumors. Currently available information on the parameters defining the pathophysiological micromilieu in human tumors is presented in this chapter. According to these data, significant var…
MR-Mammographie zur Responsekontrolle bei primärer Chemobrachytherapie des BET-inoperablen Mammakarzinoms
2001
Ziel: Evaluierung (1) moglicher storender Effekte neoadjuvanter Chemobrachytherapie auf die MR-Mammographie, (2) der Eignung der MRM zur Bestimmung der Resttumorgrose nach Therapie und (3) der Eignung der MRM zur Prognose des Gesamtansprechens nach den ersten Therapiezyklen. Methoden: 14 Patientinnen, die an einer praoperativen Tumorreduktionstherapie (4 Zyklen Chemotherapie kombiniert mit interstitieller Radiotherapie) teilnahmen, wurden mittels dynamischer MR-Mammographie (1 T, zeitliche Auflosung 93 s, raumliche Auflosung 1,9 mm, 0,1 mmol/kg GdDTPA) vor Therapie, nach den ersten beiden Chemotherapiezyklen, nach der Radiotherapie und dem dritten Zyklus sowie nach Therapieabschluss untersu…
Long-lasting tumor response on short-time administration of vemurafenib—A case report
2014
Vemurafenib has been approved since 2011 in the United States for the treatment of advanced BRAF V600–mutated melanoma as first-line therapy. Although it significantly prolongs overall and progression-free survival, most patients relapse within 6 to 8 months owing to acquisition of drug resistance. New findings suggest that discontinuous dose administration of vemurafenib might prolong response to vemurafenib, but it is unclear whether modified cell signalling or other mechanisms, such as immune-mediated effects, are responsible for this effect.
Role of Positron Emission Tomography for the Monitoring of Response to Therapy in Breast Cancer
2015
Abstract This review considers the potential utility of positron emission tomography (PET) tracers in the setting of response monitoring in breast cancer, with a special emphasis on glucose metabolic changes assessed with 18F-fluorodeoxyglucose (FDG). In the neoadjuvant setting of breast cancer, the metabolic response can predict the final complete pathologic response after the first cycles of chemotherapy. Because tumor metabolic behavior highly depends on cancer subtype, studies are ongoing to define the optimal metabolic criteria of tumor response in each subtype. The recent multicentric randomized AVATAXHER trial has suggested, in the human epidermal growth factor 2-positive subtype, a …
Positron emission tomography and neoadjuvant therapy of breast cancer
2011
The increasing use of neoadjuvant therapy for breast cancer has led to the development of early surrogate markers of response. Positron emission tomography (PET) allows noninvasive study of fundamental biologic processes in the tumor; furthermore, PET provides various markers to assess tumor response early in the course of therapy. Numerous studies have shown that changes in tumor glucose metabolism during therapy are significantly correlated with final response and patient outcome. Moreover, new PET tracers that are currently being developed or under evaluation, providing specific information on tumor characteristics or receptor expression, will assist the development of new targeted antic…
18F-FDG PET imaging of breast cancer : evaluation of the metabolic behaviour of the different breast cancer subtypes and prediction of the tumor resp…
2015
Positron Emission Tomography (PET) with 18Fluoro-deoxyglucose (18F-FDG) is the reference imaging examination for in-vivo quantification of the glucidic metabolism of tumour cells. It allows for the monitoring of tumour metabolic changes during chemotherapy. Breast cancer comprises several distinct genomic entities with different biological characteristics and clinical behaviours, leading to different tailored treatments. The aim of this doctoral thesis was to evaluate the relationship between the different biological entities of breast cancer and the tumour metabolic behaviour during neoadjuvant chemotherapy. We have also retrieved, among the various metabolic parameters on PET images, the …
Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Onc…
2023
Background: Obesity has been associated with improved response to immunotherapy in cancer patients. We investigated the role of body mass index (BMI) in patients from the ARON-1 study (NCT05287464) treated by dual immuno-oncology agents (IO+IO) or a combination of immuno-oncology drug and a tyrosine kinase inhibitors (TKI) as first-line therapy for metastatic renal cell carcinoma (mRCC). Patients and methods: Medical records of patients with documented mRCC treated by immuno-oncology combinations were reviewed at 47 institutions from 16 countries. Patients were assessed for overall survival (OS), progression-free survival (OS), and overall clinical benefit (OCB), defined as the sum of the r…
EFSUMB Guidelines 2011: Comment on Emergent Indications and Visions
2012
The focus of this article is the emergent and potential indications of contrast-enhanced ultrasound (CEUS). Emergent applications of CEUS techniques include extravascular and intracavitary contrast-enhanced ultrasound, quantitative assessment of microvascular circulation for tumor response assessment, and tumor characterization using dynamic contrast-enhanced ultrasound (DCE-US). Potential indications for microbubble agents include novel molecular imaging and drug and gene delivery techniques, which have been successfully tested in animal models. "Comments and Illustrations of the European Federation of Societies for Ultrasound in Medicine and Biology (EFSUMB) Non-Liver Guidelines 2011" whi…